WAYNE, Penn., Dec. 9, 2015 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the appointment of leading experts to its newly formed scientific advisory board (SAB).
"With the high caliber of scientific leaders joining our scientific advisory board, we will gain a critical external perspective on the potential applications of our Guardian™ Technology," said Bob Radie, president and chief executive officer of Egalet. "While the initial applications of our Guardian Technology are moving through the final stage of development, future applications of our technology platform can go beyond abuse-deterrence. We look forward to collaborating with our advisors to help guide us into new areas of growth for Egalet."
The members of Egalet's scientific advisory board include:
- Vincent Lee, Ph.D., D.Sc. research professor and former director of the School of Pharmacy at the Chinese University of Hong Kong and former chairman of the department of pharmaceutical sciences at the School of Pharmacy at the University of Southern California;
- Jacques-Pierre Moreau, D.Sc., former founder and president of Biomeasure,Inc. and chief scientific officer and executive vice president of Ipsen SA (France);
- Nicholas Nicolaides, Ph.D., president, chief executive officer and co-founder of Morphotek;
- Kenneth Shea, Ph.D., professor of chemistry at the School of Physical Science at the University of California, Irvine;
- Giovanni Traverso, M.D., Ph.D., instructor in medicine at Harvard Medical School, a gastroenterologist at the Massachusetts General Hospital and a research affiliate at the Massachusetts Institute of Technology; and
- Jeffrey Wilkins, M.D., chief medical officer of Lycera.
The newly formed SAB will serve as a strategic resource to Egalet regarding the numerous potential applications of its Guardian™ Technology.
About Egalet Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. The Company has two approved products: OXAYDO® (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX® (ketorolac tromethamine) Nasal Spray. In addition, using Egalet's proprietary Guardian™ Technology, the Company is developing a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, ARYMO®, formerly known as Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet's Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For additional information on Egalet, please visit egalet.com. For full prescribing information on SPRIX, please visit sprix.com and for OXAYDO please visit oxaydo.com. For full prescribing information on SPRIX, including the black box warning, please visit sprix.com. For full prescribing information on OXAYDO, please visit oxaydo.com.
Safe Harbor Statements included in this press release (including but not limited to upcoming milestones) that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of Egalet's clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; Egalet's ability to obtain regulatory approval of Egalet's product candidates; Egalet's ability to maintain the intellectual property position of Egalet's products and product candidates; Egalet's ability to identify and reliance upon qualified third parties to manufacture its products; Egalet's ability to service its debt obligations; Egalet's ability to find and hire qualified sales professionals; the receptivity in the marketplace and among physicians to Egalet's products; the success of products which compete with Egalet's that are or become available; general market conditions; and other risk factors described in Egalet's filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.
Investor and Media Contact: E. Blair Clark-Schoeb Senior Vice President, Communications Email: firstname.lastname@example.org Tel: 917-432-9275
SOURCE Egalet Corporation